产品编号 | 产品名称 | CAS No. |
DC9902 |
PRIMA-1
PRIMA-1 (NSC-281668) 是一种突变型 p53 复活剂,可恢复 TP53 突变型甲状腺癌细胞对组蛋白甲基化抑制剂 3-Deazaneplanocin A 的敏感性。 |
5608-24-2 |
DC9936 |
NMS-P118
NMS-P118是一种有效的,口服可用的,高选择性的PARP-1抑制剂,在HeLa细胞中的IC50值为0.04 μM。 |
1262417-51-5 |
DC9972 |
ARQ-092
Miransertib (ARQ-092) 是一种有效的选择性和变构型 Akt 抑制剂,对 Akt1,Akt2,Akt3 的 IC50 分别为 2.7 nM,14 nM 和 8.1 nM。 |
1313881-70-7 |
DC9983 |
E-7449
E7449 是 PARP1 和 PARP2 的有效抑制剂,同时可抑制 TNKS1 和 TNKS2 的活性,在以 32P-NAD+ 为底物的实验中,测得对 PARP1,PARP2,TNKS1 和 TNKS2 的 IC50 值分别为 2.0,1.0,∼50 和 ∼50 nM。 |
1140964-99-3 |
DCAPI1510 |
Ixabepilone
Ixabepilone 是一种可口服的 microtubule抑制剂,能够与微管蛋白结合,促进微管蛋白的聚合和微管的稳定,因此使细胞停滞在 G2-M 期,诱导细胞凋亡。 |
219989-84-1 |
DC7622 |
BIBX1382
Falnidamol (BIBX 1382) 是一种具有口服活性的,选择性的 EGFR 酪氨酸激酶抑制剂,IC50 为3 nM。Falnidamol 对 ErbB2 (IC50=3.4 μM) 和其他一系列相关酪氨酸激酶 (IC50>10 μM) 的选择性 >1000倍。Falnidamol 是嘧啶-嘧啶化合物,具有抗癌活性。 |
196612-93-8 |
DC7376 |
BMS777607
BMS 777607 是一种 Met-related 抑制剂,能够抑制 c-Met,Axl,Ron 和 Tyro3 的活性,IC50 值为 3.9 nM,1.1 nM,1.8 nM 和 4.3 nM。 |
1025720-94-8 |
DC11543 |
Glumetinib
Glumetinib (SCC244) 是一种高效选择性的 c-Met 激酶抑制剂,IC50 值为 0.42 nM。Glumetinib 具有抗肿瘤活性且安全性良好。 |
1642581-63-2 |
DC7220 |
OSU-03012
OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067. |
742112-33-0 |
DC8174 |
Pexmetinib(ARRY-614)
Pexmetinib 是一种有效的 Tie-2 和 p38 MAPK 双重抑制剂,对 Tie-2,p38α 和 p38β 的 IC50 值分别为 1 nM,35 nM 和 26 nM,可用于急性骨髓性白血病的研究。 |
945614-12-0 |
DC8598 |
PLK1 inhibitor GSK461364
GSK461364 是选择性,可逆,ATP竞争性的 PLK1 抑制剂,Ki 值为 2.2 nM。 |
929095-18-1 |
DC7488 |
RO4987655
RO4987655 是一种具有口服活性的选择性 MEK 抑制剂,抑制 MEK1/MEK2,IC50 为 5.2 nM。 |
874101-00-5 |
DC10632 |
Sitravatinib (MGCD516)
Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl. |
1123837-84-2 |
DC1006 |
OSI-027
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
936890-98-1 |
DC10128 |
FGF401
FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
1708971-55-4 |
DC10282 |
ML385
ML385 is a novel and specific NRF2 inhibitor. |
846557-71-9 |
DC10563 |
E-7046
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
1369489-71-3 |
DC1071 |
Vemurafenib (PLX4032)
PLX4032 (Vemurafenib, RG7204, Zelboraf, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM. |
918504-65-1 |
DC11329 |
Fadrozole (hydrochloride)
Fadrozole is a non-steroidal aromatase inhibitor (IC50s = 5 and 1.4 nM for human placental and rat ovarian microsomal aromatase, respectively). |
102676-31-3 |
DC2013 |
Bafetinib (INNO-406)
Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively. |
859212-16-1 |
DC2047 |
Crizotinib (PF-2341066)
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley. |
877399-52-5 |
DC2070 |
pan-Akt inhibitor GS690693
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
937174-76-0 |